# NCT02425891 (NCT02425891)

> A Study of Atezolizumab in Combination With Nab-Paclitaxel Compared With Placebo With Nab-Paclitaxel for Participants With Previously Untreated Metastatic Triple-Negative Breast Cancer (IMpassion130)

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT02425891
- Phase: PHASE3
- Status: COMPLETED
- Sponsor: Hoffmann-La Roche
- Conditions: Triple Negative Breast Cancer
- Interventions: Atezolizumab (MPDL3280A), an engineered anti-PDL1 antibody; Nab-Paclitaxel; Placebo
- Enrollment: 902
- Primary outcome: Progression Free Survival (PFS) According to Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 (v1.1) in All Randomized Participants
- Primary outcome: PFS According to RECIST v1.1 in Participants With Detectable Programmed Death-Ligand 1 (PD-L1)
- Primary outcome: Overall Survival (OS) in All Randomized Participants
- Primary outcome: OS in Participants With Detectable PD-L1

## Commentary we found

- YouTube: 12
- Podcasts: 12
- X threads: 6

## Order

Standard, $1,250, price fixed at order: https://www.erudio.com/contact?report=nct02425891

## Free build

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT02425891", "email": "<work email>"}; the inbox owner confirms by the emailed link.